Primary leptomeningeal lymphoma is very rare disease that is a subtype of primary central nervous system (CNS) lymphoma. Primary dural lymphoma is a subentity of primary leptomeningeal lymphoma and arises from the dura mater without systemic disease. A 47-year-old woman presented with an indolent mass in the right frontal region. The patient's physical examination demonstrated no focal neurological abnormality. Magnetic resonance imaging (MRI) study revealed a mass lesion in the right frontal region. The patient underwent a right frontal craniectomy and removal of tumor. Histological diagnosis was diffuse large B-cell lymphoma (DLBCL). The patient received chemotherapy with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP protocol) every 3 weeks for six cycles. The patient was discharged without neurological deficit and no evidence of tumor recurrence. There was no systemic dissemination of disease 72 months after the surgery. Until the optimal standard management protocol is established, the treatment should be with an individualized multidisciplinary approach and continued follow-up and clinical surveillance are recommended for every patient.
INTRODUCTION
Primary leptomeningeal lymphoma is very rare disease that is a subtype of primary CNS lymphoma. Primary CNS lymphoma is an extranodal non-Hodgkin's lymphoma (1, 5) and accounts for less than 1% of all non-Hodgkin's lymphomas (12) . Primary leptomeningeal lymphoma represents less than 0.1% of all non-Hodgkin's lymphomas (15). It usually presents with nonspecific neurological symptoms and signs such as headache, meningeal signs, and cranial nerve involvement (11) .
Primary dural lymphoma is a subentity of primary leptomeningeal lymphoma and arises from the dura mater with no systemic disease (2, 7, 20) . There is no standard treatment for primary dural lymphoma due to the paucity of cases (5) .
Herein, we report a case of primary dural lymphoma with a favorable clinical course after surgery and chemotherapy.
CASE REPORT
A 47-year-old woman with no previous medical or surgical history presented to another hospital with an indolent mass in the right frontal region. She was referred to our hospital for surgical treatment after a brain MRI was performed. The patient's physical examination demonstrated no focal neurological abnormality other than a palpable right frontal mass involving the scalp. MRI study revealed mass lesion in the right frontal region which appeared hypointense on T 1 -weighted imaging, hyperintense on T 2 -weighted imaging, and homogeneously enhanced after administration of gadolinium ( Figure 1A, B) . The mass measured 4 cm (lateral) x 3 cm (anteroposterior) x 1.5 cm (vertical) and invaded the skull and dura on MR imaging.
Under general anesthesia, the patient underwent a right frontal craniectomy. The tumor was gray, firm, relatively hypovascular and severely infiltrated the skull and dura. The tumor was excised en-bloc and the infiltrated bone flap and dura were removed. The dura was closed with a galeaperiosteal flap, and bone cement was molded to the defect shape used for cranioplasty (Figure 2A-D) .
A lymphoma was suspected on intraoperative frozen biopsy. Chest and abdominal CT, bone scintigraphy and bone marrow biopsy were performed to find occult systemic disease but no other systemic lymphoma was detected.
Hematoxylin and eosin stain revealed the cellular solid mass lesion that was attached to the dura and infiltrated the cranial bone marrow spaces with extensive necrosis, at low power. The large lymphoid tumor cells showed severe cellular atypism such as high nuclear/cytoplasmic ratio (N/C ratio), prominent nucleoli, irregular nuclear membrane and frequent mitoses. They reacted with the CD20 antibody, which is one a B cell marker ( Figure 3A , B). Cytokeratin, vimentin, CD3, CD45RO, and CD5 were all negative on immunohistochemical studies. The pathology diagnosis was diffuse large B cell lymphoma of the dura. After the histological diagnosis was confirmed, the patient received chemotherapy with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP) every 3 weeks for six cycles. She was discharged without neurological deficit and no evidence of tumor recurrence. There was no systemic dissemination of disease 72 months after the surgery.
DISCUSSION
The incidence of primary dural lymphoma is unknown but it is a very rare disease. The incidence of this tumor varies from 0.6% to 3% of all brain tumors (7, 20, 21 (14) .
The pathogenesis of primary dural lymphoma is unclear because the dura lacks any lymphoid tissue (5). Many hypotheses have been formulated including the role of a chronic inflammatory process, chronic infection, autoimmune diseases like scleroderma, Graves disease, Sjögren disease, and the meningoepithelial component (5, 15) .
Clinical manifestations are usually dependent on the location of the tumor. The most common symptoms are headache, seizure and meningeal signs. Cranial nerve involvement symptoms like visual and hearing disturbance, and diplopia can also be present (6,10). Goetz et al. reported a patient with unusual symptoms who had headaches and acute hemiparesis mimicking an acute subdural hematoma (4). Radicular pain and paraparesis are the most common presenting symptoms in the case of spinal primary dural lymphomas (15).
Magnetic resonance imaging reveals single or multiple dural-based extraaxial masses that diffusely enhance after administration of gadolinium (6) . The most common site is the cerebral convexities, but the falx, tentorium, sellar/ suprasellar regions and intraventricular and spine lesions can also be involved (13, 19) . En plaque thickening of meninges, dural tail sign, underlying parenchymal vasogenic edema, early invasion of the underlying brain, calvarial hyperostosis, and bone erosion have been demonstrated with magnetic resonance imaging (5).
The differential diagnosis includes meningioma, dural metastasis, solitary fibrous tumors, gliosarcomas, hemangiopericytomas, and inflammatory pseudotumors (9) . Meningioma is the first to be considered in the differential diagnosis. Both tumors share many radiographic and clinical features, including a higher incidence in women, and similar age of onset and magnetic resonance imaging findings. The presence of vasogenic edema and parenchymal brain invasion with a fuzzy tumor brain interface favors a diagnosis of primary dural lymphomas (15).
The most frequent histopathological diagnosis of primary dural lymphoma is marginal zone lymphoma (MZL) (5). Highgrade non-Hodgkin lymphoma, low-grade follicular lymphoma, and Hodgkin disease have also been rarely reported (5, 8, 13) . The pathological features of MZLs arising in the dura are similar to MZLs at other extranodal sites (22) . Our case was DLBCL, which is more common in other types of primary CNS lymphomas (5). We briefly compared the case with primary CNS lymphomas and primary dural lymphomas (Table I) .
Primary dural lymphoma is a very rare disease and there is no standard treatment. Extranodal disease limited to a single site responds favorably to surgery or focal radiation (16, 18, 22 (6) . Systemic adjuvant chemotherapy is also available. High-dose methotrexate or R-CHOP regimen is effective for parenchymal CNS lymphomas, but the effect is unclear in primary dural lymphomas. There is no guideline in terms of the standard regimen to be used so the decision should be made individually (15). If the leptomeningeal involvement is checked, intrathecal chemotherapy or wholebrain radiotherapy is required (5).
A primary dural lymphoma is more indolent and has a better prognosis than parenchymal primary CNS lymphoma or systemic lymphoma with CNS metastasis. The 5-year overall survival rate was greater than 86 % in MZLs (17) . Diffuse large B-cell type lymphoma also has a relatively benign prognosis (21) . In comparison, patients with non-Hodgkin lymphomas in the CNS have survived for 12 to 18 months (3), and only 8% have survived longer than 3 years (14) . Systemic recurrence can occur several years after the initial diagnosis of primary dural lymphomas and continued follow-up and clinical surveillance are recommended for every patient (5).
CONCLUSION
Primary dural lymphoma is very rare disease so that there is no standard treatment. It responds well to local treatments such as surgery or radiation therapy and has a favorable clinical outcome in most patients (17, 18, 22) . Systemic recurrence can occur several years after the diagnosis. Until the optimal standard management protocol is established, the treatment should be with an individualized multidisciplinary approach and continued follow-up and clinical surveillance are recommended for every patient. 
